IDEXX Laboratories, Inc. $IDXX Shares Acquired by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 62,951 shares of the company’s stock after buying an additional 6,710 shares during the period. IDEXX Laboratories accounts for approximately 1.7% of Beacon Investment Advisory Services Inc.’s portfolio, making the stock its 15th largest holding. Beacon Investment Advisory Services Inc. owned approximately 0.08% of IDEXX Laboratories worth $42,588,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its stake in shares of IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock worth $1,313,992,000 after purchasing an additional 605,290 shares during the period. Norges Bank acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $221,955,000. JPMorgan Chase & Co. grew its position in shares of IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after purchasing an additional 326,348 shares during the period. Schroder Investment Management Group increased its stake in IDEXX Laboratories by 295.1% in the second quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after purchasing an additional 235,863 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI acquired a new position in IDEXX Laboratories in the third quarter valued at $143,730,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This represents a 69.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $558.32 on Monday. The firm has a market capitalization of $44.40 billion, a P/E ratio of 42.72, a P/E/G ratio of 3.39 and a beta of 1.66. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The business’s 50-day simple moving average is $631.32 and its 200-day simple moving average is $662.08.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the company earned $2.53 EPS. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Barclays decreased their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. BTIG Research cut their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. UBS Group decreased their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Piper Sandler cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.